Abstract
HIV enters cells through critical interactions of the viral envelope protein (Env) with the CD4 receptor and a chemokine coreceptor, typically CCR5 or CXCR4 [1]. This chapter focuses on these two most clinically relevant coreceptors. Based upon the pattern of coreceptor utilization, a virus may be classified as exhibiting one of three phenotypes; a virus using only CCR5 is R5 tropic, one that uses only CXCR4 is X4 and one that can use either coreceptor is R5X4 or dual tropic. Since HIV commonly exists within a patient as a mixture of viruses with different tropisms, there is a fourth possible determination, mixed tropism. For example, a single HIV plasma sample may contain R5 as well as X4 or R5X4 viruses. Population-based coreceptor typing assays cannot distinguish between truly dual tropic viral populations and those that are mixed. Therefore the detection of both R5 and X4 tropism in a sample is reported as dual/mixed (DM).
Keywords
- Human Immunodeficiency Virus Type
- West Nile Virus
- CCR5 Antagonist
- Coreceptor Usage
- Optimize Background Therapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Doranz BJ, Berson JF, Rucker J, Doms RW (1997) Chemokine receptors as fusion cofactors for human immunodeficiency virus (HIV-1). Immunol Res 16: 15–28
Koot M, Vos AHV, Keet RPM, de Goede RE, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M (1992) HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 6: 49–54
The ACTG Virology Technical Advisory Committee and the Division of AIDS, National Institutes of Health (1997) The ACTG Virology Manual for HIV laboratories. NIH, Bethesda 1997
Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M (1993) Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118: 681–688
Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heverker N, Alizon M, Scarlatti G, Clavel F, Mammano F (2001) Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 75: 251–259
Huang W, Wrin M, Yap J, Fransen S, Beauchaine T, Reddy M, Paxinos EE, Parkin NT, Whitcomb JM, Petropoulos CJ (2001) A rapid multi-functional HIV-1 entry assay for measuring drug susceptibility, coreceptor tropism, and antibody neutralization. 41st Interscience Conference on Antimicrobial Agents and Chemotherapeutics; December 2001, Chicago, IL, abstr. no. I-1968
Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss L, Paxinos EE, Petropoulos CJ (2007) Development and characterization of a novel single-cycle recombinant virus assay to determine human immunodeficiency virus type-1 co-receptor tropism. Antimicrob Agents Chemother. 51: 566–575
The AMD3100 HIV Study Group (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253–1262
Gulick R, Su Z., Flexner C et al., for the ACTG 5211 Study Team (2006) ACTG 5211: Phase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects. Program and abstracts of the XVI International AIDS Conference; August 13–18, 2006, Toronto, Ontario, abstr. no. THLB0217
Hosoya N, Su Z, Wilkin T, Gulick R, Flexner C, Hughes M, Skolnik P, Greaves W, Coakley E, Kuritzkes D (2006) Assessing HIV-1 tropism in ACTG 5211: A comparison of assays using replication competent virus from peripheral blood mononuclear cells versus plasma-derived pseudotyped virions. Abstracts of the 2nd International Workshop Targeting HIV Entry; October 20–21, 2006, Boston, abstr. no. 33
Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R (2002) Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 76: 3852–3864
Pillai S, Good B, Richman D, Corbeil J (2003) A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 19: 145–149
Jensen MA, Li FS, van’ t Wout AB, Nickle DC et al. (2003) IImproved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376–13388
Sing T, Beerenwinkel N, Lengauer T (2004) Learning mixtures of localized rules by maximizing the area under the ROC curve. 16th European Conference on Artificial Intelligence (ECAI), Workshop on ROC Analysis in AI, 2004
Stawiski E, Liu Y, Toma J, Huang W, Fransen S, Whitcomb J, Coakley E, Parkin N, Eshleman S, Petropoulos C, Chappey C (2006) Limitations in predicting HIV-1 co-receptor tropism from V3 genotype data. XVI International AIDS Conference, Toronto, Canada, August 13–18, 2006, abstr. no. THPE0046
Huang W, Eshelman S, Toma J, Fransen S, Stawiski E, Jackson B, Whitcomb J, Parkin N, Petropoulos C (2006) CXCR4 use is common in subtype D HIV-1; Co-receptor tropism determinants exist outside of the V3 region of gp120. Abstracts of the 2nd International Workshop Targeting HIV Entry; October 20–21, 2006, Boston, abstr. no. 7
Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS, Harrigan PR (2005) Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 192: 466–474
Wilkin T, Su Z, Kuritzkes D, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR (2006) Co-receptor tropism in patients screening for ACTG 5211, a phase 2 study of vicriviroc, a CCR5 inhibitor. Clin Infect Disease 44: 591–595
Demarest J, Bonny T, Vavro C, LaBranche C, Kitrinos K, McDanal C, Sparks S, Chavers S, Castillo S, Elrick D (2004) HIV-1 co-receptor tropism in treatment naive and experienced subjects. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 30–November 2, 2004, Washington, DC, abstr. no. H-1136
Melby T, Despirito M, Demasi R, Greenberg M (2006) HIV-1 Co-receptor tropism in triple-class-experienced patients: baseline correlates and relationship to enfuvirtide response. Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 5–9, 2006, abstr. no. 233
Hunt PW, Harrigan PR, Huang W (2006) Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 194: 926–930
Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA (2003) High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 77: 7682–7688
Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD (1993) A cross-sectional comparison of persons with syncytium-and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 168: 1374–1379
Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kurtizkes DR, Scott WA, Spector SA, Basgoz N et al. (1997) Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 126: 929–938
Japour AJ, Welles S, D’Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR (1995) Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis 171: 1172–1179
Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D’Aquila RT et al. (1998) Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200–500 CD4 cells/mm3 (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 177: 617–624
Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W (1993) The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7: 1159–1166
Spijkerman I, de Wolf F, Langendam M, Schuitemaker K, Coutinho R (1998) Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. J Infect Dis 178: 397–403
Daar E, Kesler K, Wrin T, Petropoulos C, Bates M, Huang W, Hellmann N, Gomperts E, Donfield S and the Hemophila Growth and Development Study (2003) HIV co-receptor tropism (CRT) and replication capacity (RC) predict HIV progression. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapeutics, September 14–17, 2003, Chicago, IL, abstr. no. H-1722c
Van Rij RP, Blaak H, Visser JA et al (2000) Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest 106: 1569
Shepherd J, Jacobson L, Qiao W et al. (2006) Analysis of the timing of CXCR4-tropic HIV emergence in the MACS cohort. AIDS 2006-XVI International AIDS Conference, Toronto, Canada, August 13–18, 2006, abstr. no. TUPE0001
Samson M, Libert F, Doranz BJ (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722–725
Glass WG, McDermott DH, Lim JK (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203: 35–40
The AMD3100 HIV Study Group (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253–1262
Mayer E, van der Ryst E, Saag M, Clotet B, Fätkenheuer G, Clumeck N, Turner K, Goodrich JM (2006) Safety and efficacy of Maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. Program and abstracts of the XVI International AIDS Conference; August 13–18, 2006; Toronto, Ontario, abstr. no. THLB0215
Westby M, Whitcomb J, Huang W, James I, Abel S, Petropoulos C, Perros M, Van der Ryst E (2004) Reversible predominance of CXCR4 utilizing variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857. Abstracts of 11th Conference on Retroviruses and opportunistic Infections; February 8–11, 2004, San Francisco, CA, 538
Kitrinos K, LaBranche C, Stanhope M (2005) Clonal analysis detects pre-existing R5X4-tropic virus in patient demonstrating population-level tropism shift on 873140 monotherapy. Antiviral Ther10: S68
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Coakley, E. (2007). The utility of coreceptor typing in the clinic. In: Reeves, J.D., Derdeyn, C.A. (eds) Entry Inhibitors in HIV Therapy. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7783-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7783-0_9
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7782-3
Online ISBN: 978-3-7643-7783-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)